Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
Restricted accessBrief reportFirst published online May, 2020
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS).
Methods
We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature.
Results
Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms.
Conclusion
Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.
RuffattiATarziaVFedrigoM, et al.
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev2019;
18: 561–563.
2.
GuillotMRafatCBuobD, et al.
Eculizumab for catastrophic antiphospholipid syndrome – a case report and literature review. Rheumatology (Oxford)2018;
57: 2055–2057.
3.
WigSChanMThachilJBruceIBarnesT.A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford)2016;
55: 382–384.
4.
StrakhanMHurtado-SbordoniMGaleasNBakirhanKAlexisKElrafeiT.36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol2014;
2014: 704371.
5.
ZikosTASokoloveJAhujaNBerubeC.Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol2015;
21: 311–313.
6.
TintiMGCarnevaleVIngleseM, et al.
Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med2019;
19: 281–288.
7.
Barratt-DueAFløisandYOrremHL, et al.
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford)2016;
55: 1337–1339.
8.
KronbichlerAFrankRKirschfinkM, et al.
Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore)2014;
93: e143.
9.
ShapiraIAndradeDAllenSLSalmonJE.Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum2012;
64: 2719–2723.
CerveraRPietteJ-CFontJ, et al.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002;
46: 1019–1027.
12.
AshersonRACerveraRDe GrootPG, et al.
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus2003;
12: 530–534.
13.
Rodríguez-PintóIMoitinhoMSantacreuI, et al.
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev2016;
15: 1120–1124.
14.
LegaultKSchunemannHHillisC, et al.
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost2018;
16: 1656–1664.
15.
RitisKDoumasMMastellosD, et al.
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol2006;
177: 4794–4802.
16.
ChaturvediSBrodskyRAMcCraeKR.Complement in the pathophysiology of the antiphospholipid syndrome.Front Immunol2019;
10: 449.
17.
PierangeliSSGirardiGVega-OstertagM, et al.
Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum2005;
52: 2120–2124.
18.
ChaturvediSBraunsteinEMYuanX, et al.
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood2020;
135: 239–251.
